home All News open_in_new Full Article

Estados Unidos concede a PharmaMar la revisión prioritaria para Zepzelca en combinación con Tecentriq

La agencia estadounidense (FDA) dará una respuesta a la solicitud en un plazo de seis meses. Más información: Sylentis (PharmaMar) recibirá una subvención de 21,1 millones de los fondos Next Generation


today 3 w. ago attach_file Politics

attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Events
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics


ID: 1063709230
Add Watch Country

arrow_drop_down